Premium
Therapeutic effect of A vonex, R ebif and B etaferon on quality of life in multiple sclerosis
Author(s) -
Mokhber Naghmeh,
Azarpazhooh Amir,
Orouji Elias,
Khorram Bita,
Modares Gharavi Morteza,
Kakhi Sorayya,
Khallaghi Hoda,
Azarpazhooh Mahmoud Reza
Publication year - 2015
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/pcn.12308
Subject(s) - multiple sclerosis , quality of life (healthcare) , medicine , mental health , randomization , physical health , physical therapy , clinical trial , sf 36 , disease , health related quality of life , psychiatry , nursing
Aims The aim of this study was to evaluate the effect of various disease‐modifying therapies ( DMT ) on quality of life in multiple sclerosis ( MS ). Methods This was a three‐arm parallel study with balanced randomization in which 90 newly diagnosed, definite MS subjects referred to G haem M edical C enter, M ashhad, I ran were enrolled between 2006 and 2009. Patients were randomly allocated into three DMT groups: A vonex, R ebif and B etaferon. Health‐related quality of life was assessed in MS patients at baseline and 12 months after treatment with DMT using the MS Quality of Life‐54 questionnaire. Results Both mental and physical health scores improved within all three treatment groups after 12 months of treatment; however, this increase was only significant in the mental health composite in the B etaferon group ( P = 0.024). Betaferon had the highest mental health score change (14.04) while this change was 7.26 for A vonex ( P = 0.031) and 5.08 for R ebif ( P = 0.017). A physical health composite score comparison among the three treatment groups revealed no significant results. Conclusions With a positive impact of DMT on mental and physical dimensions of QOL in MS patients, initiation of treatment soon after diagnosis is recommended. In MS patients with more mental issues and fewer physical disabilities, B etaferon might be considered as a better choice of treatment.